AmWINS Group Logo

  Client Update
IN THIS UPDATE
New Client Advisory:
Protecting Self-Funded Plans
Product Spotight: Communitas
Client Advisory:
The Impact of FDA Preemption
Did You Know?
AmWINS Group Benefits has a proprietary life and disability product...

...that offers coverage down to two enrolled lives with Short-Term and Long-Term Disability all non-medically underwritten?

Click www.mag-eb.com to learn more.
 
AMWINS.COM GETS A NEW LOOK IN 2011

 

What does the new amwins.com mean for you? Improved navigation and product information means you'll be able to find what and who you're looking for... fast!

We're excited about the changes, and you'll be the first to know when the site goes live in February. Stay tuned!

AMWINS AND
ST. BALDRICK'S

 

The St. Baldrick's event at our annual producer conference concluded with seven shaved heads and over $250,000 raised to help defeat kid's cancer. And donations are still being tallied!

Read more:
amwins.com/stbaldricks

Questions?

If you have a question about this newsletter, please contact:

  

Lisa Kuszmar

704.749.2780

lisa.kuszmar@amwins.com




Find us on Facebook      Follow us on Twitter      View our profile on LinkedIn
Join Our Mailing List 

January 2011

The federal Medical Loss Ratio (MLR) rules have been issued, and the details pretty much confirm what everyone has known all along; this isn't going to work unless there are multiple escape hatches for everyone, except those not clever enough to find a way out. And since the system is not uniform, any value it was ever envisioned to have will be steadily eroded while the costs of proving compliance rise over time.
 

It's a particularly poor deal for agents and brokers, whose commissions got left out in the cold. They are going to suffer the first effects as carriers squeeze their compensation to leave room in the administrative cost category for other things corporate leaders value more, like profits and high salaries.
 

However, like the old saying goes, when one door closes, another one opens.  In this case, that door for brokers is Self-Funding. Read more in January's Client Update on the opportunities that abound.


Sam Fleet

NEW CLIENT ADVISORY: Protecting Self-Funded Plans
Self-funding may sound scary to some employers, especially in a climate of high-cost medical care. A recent study found that the rate of $1 million medical claims in 2000 was less than one per every million covered members; by 2005, the rate was 11 claims per million. Many companies cannot afford to take the chance of having an employee need high-cost services. Here are six strategies to reduce the risk an employer takes on when it self-funds. Read more...


For more information about how AmWINS can help with self-funded plans,
contact Lisa Kuszmar at lisa.kuszmar@amwins.com or 704.749.2780.
 

PRODUCT SPOTLIGHT: Communitas

Always seeking a better way, AmWINS has developed the Communitas program to empower local healthcare providers and employer coalitions, who want to drive the management of premium dollars within their own communities. Read more...
 

For information about Communitas, contact Nicole Moore at WEB-TPA, at nmoore@webtpa.com or 469.417.1844.
 

NEW CLIENT ADVISORY: FDA Preemption's Impact on Life Sciences Risk Management and the Insurance Community
MedicineFederal preemption is the notion that, if the FDA approves a drug or medical device, injured patients should not be able to sue manufacturers by alleging defective warnings. In recent years, it has served as one of the ways drug and medical device firms have protected themselves from the financial cost of product liability. Preemption's viability has often been an assumption in underwriting coverage for FDA-approved drugs and devices. As preemption comes under attack, what are the implications? Read more...

To learn how AmWINS can help with your accounts that may be impacted by changes in FDA preemption, contact Sarah Ruble, 704.749.2855, sarah.ruble@amwins.com.